Remedium raises $2.3 million in seed funding

Remedium is a developer of novel gene therapies with an approach focused on combining proven technologies in a modular fashion to treat disease pathologies, thereby simplifying and reducing the risk element of the product development process. The product line includes drug candidates for the treatment of osteoarthritis, and gene therapy drugs for the treatment of type 1 and type 2 diabetes. Recently, Remedium announced the completion of a seed round of more than $2.3 million, led by Sherwood Ventures, and other investors including LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures and Guindy Alumni Angels.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment